According to the new research report published by Precedence Research, titled “Veterinary Dermatology Drugs Market (By Animal Type: Companion Animal, Livestock Animal; By Route of Administration: Oral, Topical, Injectable; By Indication: Parasitic Infections, Allergic Infections, Others; By Distribution Channel: Retail, E-Commerce, Hospital Pharmacies) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030 (By Product: Traditional, Advanced; By Application: Pottery, Tiles, Abrasives, Sanitary wave, Bricks & pipes, Others; By End User: Medical, Industrial, Building & Construction, Others) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030”, the global veterinary dermatology drugs market size is expected to be worth around US$ 20.95 billion by 2030 and is poised to record a yearly growth rate of 10.76% from 2022 to 2030. The study investigates several elements and their consequences on the growth of the all-wheel drive market.
This report focuses on veterinary dermatology drugs market volume and value at the global level, regional level and company level. From a global perspective, this report represents the overall veterinary dermatology drugs market size by analysing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, the Middle East & Africa, Latin America, etc.
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Download a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2418
The study also provides important advancements in organic and inorganic growth strategies in the worldwide veterinary dermatology drugs market. A lot of corporations are prioritizing new launches, product approvals, and other business expansion techniques. In addition, the report offers profiles of veterinary dermatology drugs market firms and market strategies. Furthermore, the research focuses on top industry participants, providing information such as company profiles, components and services offered, recent financial data, and key developments.
Veterinary Dermatology Drugs Market Report Scope
| Report Coverage | Details |
| Market Size in 2022 | USD 9.25 Billion |
| Market Size by 2030 | USD 20.95 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 10.76% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered |
|
Also read: US Virtual Care Market Size to Worth US$ 51.2 Billion by 2030
Market Key Players
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the veterinary dermatology drugs market.
Some of the prominent players in the veterinary dermatology drugs market include
- Merial, Zoetis, Inc.
- Ceva Sante Animale
- Vetmedica
- IDEXX Laboratories
- Vetoquinol S.A.
- Virbac S.A.
- Bayer Animal Health
- Boehringer Ingelheim
- Elanco
- Novartis Animal Health
- SAVAVET
- Toray Industries
- AB Science
Veterinary Dermatology Drugs Market Segmentations
By Animal Type
- Companion Animal
- Livestock Animal
By Route of Administration
- Oral
- Topical
- Injectable
By Indication
- Parasitic Infections
- Allergic Infections
- Others
By Distribution Channel
- Retail
- E-Commerce
- Hospital Pharmacies
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, segment, and project the global market size for veterinary dermatology drugs market
- To understand the structure of the market by identifying its various sub-segments
- To provide detailed information about the key factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
- To analyse the micro-markets, with respect to individual growth trends, future prospects, and their contributions to the total market
- To project the size of the market and its submarkets, in terms of value, with respect to global. (along with their respective key countries)
- To profile key players and comprehensively analyse their core competencies
- To understand the competitive landscape and identify major growth strategies adopted by players across the globe.
- To analyse the competitive developments such as expansions & investments, new product launches, mergers & acquisitions, joint ventures, and agreements
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Veterinary Dermatology Drugs Market
5.1. COVID-19 Landscape: Veterinary Dermatology Drugs Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Veterinary Dermatology Drugs Market, By Animal Type
8.1. Veterinary Dermatology Drugs Market, by Animal Type, 2022-2030
8.1.1. Companion Animal
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Livestock Animal
Chapter 9. Global Veterinary Dermatology Drugs Market, By Route of Administration
9.1. Veterinary Dermatology Drugs Market, by Route of Administration, 2022-2030
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Topical
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Injectable
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Veterinary Dermatology Drugs Market, By Indication
10.1. Veterinary Dermatology Drugs Market, by Indication, 2022-2030
10.1.1. Parasitic Infections
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Allergic Infections
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Veterinary Dermatology Drugs Market, By Distribution Channel
11.1. Veterinary Dermatology Drugs Market, by Distribution Channel, 2022-2030
11.1.1. Retail
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. E-Commerce
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Hospital Pharmacies
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Veterinary Dermatology Drugs Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.1.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.3. Market Revenue and Forecast, by Indication (2017-2030)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Indication (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Indication (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.2.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.3. Market Revenue and Forecast, by Indication (2017-2030)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Indication (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Indication (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Indication (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Indication (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.3.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.3. Market Revenue and Forecast, by Indication (2017-2030)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Indication (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Indication (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Indication (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Indication (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.3. Market Revenue and Forecast, by Indication (2017-2030)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Indication (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Indication (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Indication (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Indication (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.3. Market Revenue and Forecast, by Indication (2017-2030)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Indication (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Indication (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 13. Company Profiles
13.1. Merial, Zoetis, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Ceva Sante Animale
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Vetmedica
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. IDEXX Laboratories
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Vetoquinol S.A.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Virbac S.A.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Bayer Animal Health
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Boehringer Ingelheim
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Elanco
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Novartis Animal Health
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Why should you invest in this report?
If you are aiming to enter the global veterinary dermatology drugs market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for veterinary dermatology drugs are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
